AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00580333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Postoperative: Given intravenously for four two-week cycles
Study NCT00580333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
Study NCT00975273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capnometry Assisted Respiration Training
Description: Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
Study NCT00975273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Awareness
Description: Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
Study NCT01745484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPECT-based treatment plan
Description: SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.~The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated
Study NCT03373409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 90mcg
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 90mcg will be given on one of the 3 treatment days. One inhalation from the DPI will be used.
Study NCT03373409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol DPI 180mcg
Description: Albuterol unit dose disposable DPI delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the DPI will be used to deliver the 180mcg dose
Study NCT03373409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol HFA MDI
Description: Albuterol HFA MDI delivers 90mcg of albuterol with each inhalation. Albuterol 180mcg will be given on one of the 3 treatment days. Two inhalations from the MDI will be used to deliver the 180mcg dose
Study NCT02845102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Post Feasibility
Description: The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
Study NCT00021229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: * Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)~* Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses.
Study NCT00021229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: local irradiation therapy
Description: * Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.~* Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.
Study NCT00732342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Prizes given for targeted behavior of abstinence
Study NCT04209218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone (10 mg/2 ml) is administered before anesthesia induction.
Study NCT04209218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted blood pressure management
Description: Blood pressure is maintained within ±10% from baseline.
Study NCT04209218 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.
Study NCT04209218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (2 ml normal saline) is administered before anesthesia induction.
Study NCT04209218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine blood presure management
Description: Blood pressure is maintained according to routine practice.
Study NCT04209218 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine blood presure management
Description: Blood pressure is maintained according to routine practice.
Study NCT04397250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: Arm-cranking exercise
Study NCT02268188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education
Description: Attend classes as part of Harvesting Health program
Study NCT02268188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrition intervention
Description: Learn how to incorporate nutrition guidelines into daily meal plans as part of Harvesting Health program
Study NCT02268188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Use FitBit to log daily steps as part of Harvesting Health program
Study NCT02268188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02268188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02268188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT04401579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study NCT04401579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib is a Janus kinase (JAK) inhibitor with the chemical name \[1-(ethylsulfonyl)-3-(4-(7Hpyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl\]acetonitrile Each tablet contains 2 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, ferric oxide, lecithin (soya), polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
Study NCT01987024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actim Partus® test
Study NCT01987024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual procedure
Study NCT02681107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: APBI 27Gy in 5 fractions
Description: Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
Study NCT01032759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: 20 mg, BID
Study NCT01032759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: BID
Study NCT02775227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Study NCT02775227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Study NCT02948205 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: normal group
Description: infertility patient get normal laparoscopic surgery
Study NCT03628612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AUTO CAR T cell therapy
Description: No study drug is administered in this study. Patients previously treated with AUTO CAR T cell therapy will be monitored for safety following the first infusion.
Study NCT01518517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRASPA
Description: one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
Study NCT01518517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-asparaginase
Description: 3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
Study NCT02672345 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
Study NCT01754545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplas infusion and placebo (group 1)
Description: Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
Study NCT01754545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplas infusion and placebo (group 2)
Description: Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
Study NCT01015794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine hydrochloride
Description: single oral dose, 1mg/kg body weight
Study NCT01015794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ephedrine hydrochloride
Description: single dose of 1 mg/kg body weight
Study NCT01849185 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Food supplement
Study NCT01849185 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food supplement
Study NCT01892982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Education tailored to NICU
Study NCT01618175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Description: Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.~During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration.
Study NCT01577706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Alprazolam, gel-capsule, 1mg, single-dose, 1-day
Study NCT01577706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
Study NCT01577706 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, gel-capsule, single-dose, 1-day
Study NCT04418882 — intervention group
Intervention type: OTHER
Intervention: management and follow up of all open fractures
Description: to evaluate the development of sepsis after an open fracture and then, if there is a development of a pseudarthrosis too.
Study NCT03335553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified dose on specified days
Study NCT03335553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01093794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 500 mg metformin
Description: Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
Study NCT01093794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/500 mg tablet
Description: Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
Study NCT01093794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 850 mg metformin
Description: Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
Study NCT01093794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/850 mg tablet
Description: Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
Study NCT00566228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation
Study NCT00566228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: autologous hematopoietic stem cell transplantation
Description: Patients undergo autologous stem cell transplantation
Study NCT00566228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Stem cells collected
Study NCT00566228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: leukapheresis
Description: Stem cells collected
Study NCT01627249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0 mg intravitreal aflibercept
Description: Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
Study NCT01627249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25 mg intravitreal bevacizumab
Description: Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
Study NCT01627249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 mg intravitreal ranibizumab
Description: Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
Study NCT03109600 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-DT (Bio Farma)
Description: Typhoid Conjugate Vaccine
Study NCT03109600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi polysaccharide vaccine
Description: Vi polysaccharide vaccine
Study NCT03109600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenzae vaccine
Description: 1 dose of Influenzae vaccine
Study NCT03109600 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Description: 1 dose of Pneumococcal conjugate Vaccine
Study NCT02518659 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Inulin
Description: This is the Intervention
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20 mg by mouth daily from Day -9 to -2.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 60 mg/m2 by vein on Days -3 and -2.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg by vein twice a day from Day -8 AM to Day -2 PM.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
Study NCT02961816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Cryotherapy (ice chips)
Description: Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
Study NCT02961816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 100 mg by vein or mouth three times a day from Day -1.
Study NCT02961816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem cells administered by vein on Day 0.
Study NCT04497090 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixed-EPAP
Description: In the fixed-EPAP mode, the device kept EPAP fixed at the prescribed value
Study NCT04497090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: auto-EPAP
Description: In the Auto-EPAP mode, the device automatically adjusted EPAP to the minimum level able to abolish tidal expiratory flow limitation.
Study NCT02579785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mhealth intervention
Description: A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
Study NCT02077751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biotin labelled RBCs
Description: Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
Study NCT02530879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole, Lansoprazole, Esomeprazole, Rantidine
Description: 1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
Study NCT02530879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy
Description: Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.